Connor Clark & Lunn Investment Management Ltd. Acquires 101,666 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Connor Clark & Lunn Investment Management Ltd. boosted its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 16.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 725,355 shares of the company’s stock after acquiring an additional 101,666 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.96% of Kiniksa Pharmaceuticals International worth $28,166,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC raised its holdings in Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after purchasing an additional 532 shares in the last quarter. Osaic Holdings Inc. bought a new stake in shares of Kiniksa Pharmaceuticals International during the 2nd quarter valued at about $31,000. USA Financial Formulas purchased a new position in shares of Kiniksa Pharmaceuticals International during the third quarter valued at about $32,000. Quantbot Technologies LP bought a new position in Kiniksa Pharmaceuticals International in the second quarter worth about $43,000. Finally, Farther Finance Advisors LLC raised its stake in Kiniksa Pharmaceuticals International by 582.4% in the third quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company’s stock worth $53,000 after buying an additional 1,159 shares in the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ KNSA opened at $46.07 on Friday. The company has a 50 day simple moving average of $43.75 and a two-hundred day simple moving average of $40.58. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $18.25 and a fifty-two week high of $49.12. The company has a market capitalization of $3.53 billion, a price-to-earnings ratio of 62.26 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12). The company had revenue of $202.13 million during the quarter, compared to the consensus estimate of $200.86 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The business’s revenue for the quarter was up 65.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.12) earnings per share. On average, analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

KNSA has been the topic of several research reports. Zacks Research raised Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Canaccord Genuity Group initiated coverage on Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They issued a “buy” rating and a $62.00 target price for the company. Wells Fargo & Company raised their target price on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Wedbush upped their price target on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Kiniksa Pharmaceuticals International has a consensus rating of “Moderate Buy” and an average target price of $55.29.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, Director Barry D. Quart sold 20,129 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $41.51, for a total value of $835,554.79. Following the completion of the transaction, the director owned 12,546 shares of the company’s stock, valued at $520,784.46. The trade was a 61.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eben Tessari sold 12,048 shares of the company’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $41.56, for a total transaction of $500,714.88. Following the completion of the transaction, the chief operating officer owned 16,666 shares in the company, valued at approximately $692,638.96. The trade was a 41.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 80,782 shares of company stock worth $3,458,916. 53.48% of the stock is owned by insiders.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.